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Currently, many difficulties are encountered in
the identification of mycobacteria from clinical
samples.1–3 Although sputa are still the main sam-
ple sources, the number of mycobacterial infections
identified in nodes, pleura and osteoarticular sites
are increasing.4 Besides Mycobacterium tuberculo-
sis complex (MTBC), due to some M. bovis BCG
vaccination problems, further differentiation of
M. tuberculosis (MTB) from MTBC is also essen-
tial on some occasions.5,6 Furthermore, the isola-
tion rate of nontuberculous mycobacteria (NTM)
has been increasing, ranging from 30% to 50%
of mycobacterial isolates reported from many
hospital mycobacteriology laboratories in recent
years.6–8 This is not due to sample contamination
but, rather, has been ascribed to the use of sensitive
broth culture systems such as MGIT (Mycobacteria
Growth Indicator Tube; BD, USA) for mycobac-
teria detection.9 Although the clinical significance
of many NTM remains to be evaluated, emerging
infections cannot be ruled out and diagnostic
systems need to be improved.7 Traditional X-ray
radiography, acid fast bacilli (AFB) staining and
culture methods will, gradually, not be able to cope
with clinical requirements. The efficacy of current
nucleic acid hybridization-based detection sys-
tems (including chips, arrays or liquid detection
systems) is still not satisfactory as only a limited
number of mycobacteria can be identified.10,11
Instead, emerging rapid and large-scale nucleic acid
sequencing technology such as pyrosequencing
might increasingly play important roles in appli-
cation.12,13 Furthermore, samples other than sputa
are characterized by few mycobacterial cells and
the existence of complex PCR inhibitors.14–16 Thus,
methods for increasing the efficiency of nucleic
acid purification and increasing the detection limits
must be improved.10
Another problem encountered is HIV infection
and the problems of multi-drug resistant (MDR)/
extended drug-resistant (XDR) MTB.17–19 Although
the current MDR/XDR drug resistance ratio is not
very high (< 10%), the situation must be moni-
tored carefully. More rapid and accurate drug re-
sistance detection methods such as direct DNA
amplification and sequencing, electrophoresis and
hybridization have to be developed and applied,
in addition to the traditional antibiotic dilution
methods.20 Furthermore, how the detection of la-
tent infections from the community population
can be improved is another important issue.21
While traditional antibody-antigen serodiagno-
sis assay by ELISA or related approaches are not
practically applicable, in vitro QuantiFERON-TB
and T SPOT TB assays22 based on the production
of interferon-γ by T lymphocytes seem to be a
promising method for the detection of latent in-
fections.23–25 However, in future, in vivo testing of
latent infection by ESAT-6 and CFP-10 to replace
tuberculosis/PPD skin test (TST) assay might be
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a more efficient and practicable approach. But this
needs further large-scale evaluation.
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